Abstract:Background: Pulmonary arterial hypertension (PAH) is a rare but severe and life-threatening condition that primarily affects the pulmonary blood vessels and the right ventricle of the heart. The limited availability of human tissue for research ~most of which represents only end-stage disease~ has led to a reliance on preclinical animal models. However, these models often fail to capture the heterogeneity and complexity of the human condition. Analyzing the molecular signatures in patient plasma provides a unique opportunity to gain insights into PAH pathobiology, explore disease heterogeneity absent in animal models, and identify potential therapeutic targets. Objective: This study aims to characterize the circulating peptides, metabolites, and lipids most relevant to PAH by leveraging unbiased mass spectrometry and advanced computational tools. Building on prior research that identified individual circulating factors, this work seeks to integrate these molecular layers to better understand their interactions and collective contribution to PAH pathobiology. Methods: Peripheral blood samples were collected from 402 patients with PAH and 76 healthy individuals. Various types of molecules in the blood ~ peptides, metabolites, and lipids ~ were measured. Statistical and machine learning methods were used to identify differences between PAH patients and healthy individuals, and further to understand how these molecules might interact with each other. A survival model was also trained to examine the association between the blood molecular signature and patient outcomes. Results: Differential abundance analysis revealed 832 peptides (from 291 proteins), 45 metabolites, and 222 lipids significantly altered in PAH compared to controls. Machine learning-based feature selection identified 11 key molecules, including 2~Hydroxyglutarate, that together achieved a classification accuracy of 98.6% for PAH in a multivariate model tested on a withheld cohort. Latent network discovery uncovered 7 distinct networks, highlighting interacting molecules from pathways ~such as hypoxia, glycolysis, fatty acid metabolism, and complement activation~ that we and others have previously linked to vascular lesions in PAH patients. A survival model incorporating 155 molecular features predicted outcomes in PAH patients with a c-index of 0.762, independent of traditional clinical parameters. This model stratified patients into risk categories consistent with established markers of cardiac function, exercise tolerance, and the REVEAL 2.0 risk score. Conclusion: This study underscores the utility of integrated omics in unraveling PAH pathobiology in human subjects. Our findings highlight the central role of hypoxia signaling pathways interacting with disrupted fatty acid metabolism, complement activation, inflammation, and mitochondrial dysfunction. These interactions, revealed through latent network analysis, emphasize the metabolic and immune dysregulation underlying PAH. Furthermore, many of the molecules identified in the circulation were consistent with pathways enriched in pulmonary vascular lesions, reinforcing their biological relevance. Circulating plasma molecules from these networks demonstrated strong prognostic capabilities, comparable to current clinical risk scores, offering insights into disease progression and potential for future clinical application.

Proteomic Signatures of Right Ventricular Outcomes in Pulmonary Arterial Hypertension

Correlation Between Right Ventricular Dysfunction and Plasma Protein Profile in Pulmonary Hypertension

Proteomic and Phosphoproteomic Analysis of Right Ventricular Hypertrophy in the Pulmonary Hypertension Rat Model

Prognostic Significance of Proteomics-Discovered Circulating Inflammatory Biomarkers in Patients With Pulmonary Arterial Hypertension

Protein Biomarkers And Risk Scores In Pulmonary Arterial Hypertension Associated With Ventricular Septal Defect: Integration Of Multi-Omics And Validation

Identification of candidate biomarkers and molecular networks associated with Pulmonary Arterial Hypertension using machine learning and plasma multi-Omics analysis

Transcriptional profiling unveils molecular subgroups of adaptive and maladaptive right ventricular remodeling in pulmonary hypertension

Abstract 15564: Transcriptional Profiling Unveils New Molecular Subgroups of Adaptive and Maladaptive Right Ventricular Remodeling in Pulmonary Hypertension

Echocardiographic, Biochemical, and Electrocardiographic Correlates Associated With Progressive Pulmonary Arterial Hypertension

Defining the molecular signatures of human right heart failure

Abstract 4143932: Exploring P300/CBP as therapeutic approach for right ventricular dysfunction in PAH

Epicardial Adipose Tissue Dysfunction in Pulmonary Arterial Hypertension: Implications for Right Ventricular Dysfunction

Assessment and Prognostic Impact of Right Ventricular Function in Patients with Pulmonary Arterial Hypertension Undergoing Pulmonary Artery Denervation: Central Role of Global Right Ventricular Longitudinal Peak Systolic Strain

Right ventricular protein expression profile in end-stage heart failure

Identification of Long Noncoding RNA H19 as a New Biomarker and Therapeutic Target in Right Ventricular Failure in Pulmonary Arterial Hypertension

Abstract 387: Weighted Gene Co-Expression Network Analysis Identification and Experimental Validation of Genetic Determinants of Right Ventricular Function

Right atrial pressure/pulmonary artery wedge pressure ratio: A more specific predictor of survival in pulmonary arterial hypertension

Comparative analysis of right ventricular metabolic reprogramming in pre-clinical rat models of severe pulmonary hypertension-induced right ventricular failure

Identification of immune‐associated signatures and potential therapeutic targets for pulmonary arterial hypertension

Molecular Characterization and Elucidation of Pathways to Identify Novel Therapeutic Targets in Pulmonary Arterial Hypertension

Characterization and clinical significance of right ventricular mechanics in pulmonary hypertension evaluated with cardiovascular magnetic resonance feature tracking